Results from Trial 2: VYLOY + CAPOX

DURING THE TRIAL

VYLOY + chemotherapy helped more people live without their cancer getting worse versus chemotherapy alone.

DURING THE TRIAL

VYLOY + chemotherapy helped more people live longer versus chemotherapy alone.

Median overall survival time was 14.4 months with VYLOY + chemotherapy vs 12.2 months for chemotherapy alone

AFTER THE STUDY ENDED

Some patients being treated in Trial 2 were assessed at 1 and 2 years. These results were not used to determine how well VYLOY performed and they only reflect the experience of these patients. Your experience may be different.

At 1 year

35% of patients on VYLOY + chemotherapy were progression-free

19% of patients on chemotherapy alone were progression-free

At 2 years

14% of patients on VYLOY + chemotherapy were progression-free

7% of patients on chemotherapy alone were progression-free

At 1 year

58% of patients on VYLOY + chemotherapy were still alive

51% of patients on chemotherapy alone were still alive

At 2 years

29% of patients on VYLOY + chemotherapy were still alive

17% of patients on chemotherapy alone were still alive

What are the possible side effects of VYLOY?

Support, tools, and resources are available for anyone receiving VYLOY